Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A J Scheen

Showing results (51-60 of 787) with videos related to

Pageof 79
Sort By:
Revue Medicale De Liege|September 10, 2020
[Ertugliflozin alone and in fixed-dose combinations : «pass of three»]A J Scheen
Revue Medicale De Liege|January 6, 2016
[Humalog® 200 U/ml KwikPen™]A J Scheen
Revue Medicale Suisse|October 28, 2015
[What about all those non-inferiority trials to demonstrate the cardiovascular safety of new antidiabetic drugs?]A J Scheen
Revue Medicale De Liege|November 1, 1987
[Metabolic consequences of a 6-hour interruption of a continuous subcutaneous insulin infusion pump in insulin-dependent diabetic patients]A J Scheen
Revue Medicale De Liege|August 20, 2015
[Conventional medicine, evidence-based medicine, personalized medicine: three complementary approaches]A J Scheen
Diabetes & Metabolism|May 30, 2017
'Treatment-resistant' type 2 diabetes: Which definition for clinical practice?A J Scheen
Revue Medicale De Liege|July 1, 1992
[From obesity to diabetes or the natural history of abnormalities in the secretion and action of insulin]A J Scheen
Revue Medicale De Liege|June 22, 2018
[From atherosclerosis to atherothrombosis : from a silent chronic pathology to an acute critical event]A J Scheen
Revue Medicale De Liege|January 31, 1998
[Current drug therapies. 1996-7 (1)]A J Scheen
Revue Medicale De Liege|February 28, 1998
[Lamotrigine (Lamictal)]A J Scheen
Pageof 79

Showing results (51-60 of 787) with videos related to

Sort By:
Pageof 79
Revue Medicale De Liege|September 10, 2020
[Ertugliflozin alone and in fixed-dose combinations : «pass of three»]A J Scheen
Revue Medicale De Liege|January 6, 2016
[Humalog® 200 U/ml KwikPen™]A J Scheen
Revue Medicale Suisse|October 28, 2015
[What about all those non-inferiority trials to demonstrate the cardiovascular safety of new antidiabetic drugs?]A J Scheen
Revue Medicale De Liege|November 1, 1987
[Metabolic consequences of a 6-hour interruption of a continuous subcutaneous insulin infusion pump in insulin-dependent diabetic patients]A J Scheen
Revue Medicale De Liege|August 20, 2015
[Conventional medicine, evidence-based medicine, personalized medicine: three complementary approaches]A J Scheen
Diabetes & Metabolism|May 30, 2017
'Treatment-resistant' type 2 diabetes: Which definition for clinical practice?A J Scheen
Revue Medicale De Liege|July 1, 1992
[From obesity to diabetes or the natural history of abnormalities in the secretion and action of insulin]A J Scheen
Revue Medicale De Liege|June 22, 2018
[From atherosclerosis to atherothrombosis : from a silent chronic pathology to an acute critical event]A J Scheen
Revue Medicale De Liege|January 31, 1998
[Current drug therapies. 1996-7 (1)]A J Scheen
Revue Medicale De Liege|February 28, 1998
[Lamotrigine (Lamictal)]A J Scheen
Pageof 79